Isoquinolinone Solid Forms for Consistent PI3K Inhibitor Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing PI3K inhibitors lack scalability, efficiency, and consistency in solid state characteristics, which affect the quality, safety, and efficacy of drug products, necessitating a need for a process that is safe, scalable, and economically viable.
Innovation Solution
Development of solid forms of PI3K inhibitors, including crystalline forms, cocrystals, and amorphous forms, with specific properties such as improved powder flow, compaction, and stability, along with methods for their synthesis and analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing PI3K inhibitors are used, then the production process is simple, but the scalability and efficiency are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing reaction conditions including temperature ranges (0°C to 100°C), solvent selection (water, alcohols, esters, ketones, nitriles), pH levels (pH 2-12), and reaction time (1 hour to 24 hours) to transform the production process into one that is both scalable and efficient while maintaining simplicity
2Manufacturing precision
If current methods for producing PI3K inhibitors are used, then the process is easy to implement, but consistency in solid state characteristics is insufficient
Solution Approach 1:
The patent achieves consistent solid state characteristics (polymorph, solvate, hydrate, amorphous form, particle size, shape, and surface properties) by controlling manufacturing parameters including solvent type, temperature, pH, and reaction time, while keeping the process easy to implement through straightforward reaction conditions
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring and controlling reaction parameters to ensure consistent solid state characteristics, using analytical methods to verify polymorph formation and adjusting conditions to maintain manufacturing consistency
3Reliability
If current methods for producing PI3K inhibitors are used, then the process is simple, but the quality and safety of drug products are compromised
Solution Approach 1:
The patent improves quality and safety by optimizing reaction parameters including temperature control (0°C to 100°C), pH adjustment (pH 2-12), solvent selection from pharmaceutically acceptable solvents, and reaction time control (1-24 hours), ensuring consistent production of high-quality PI3K inhibitors with controlled solid state characteristics
Solution Approach 2:
The patent converts potential harmful effects into benefits by using water and environmentally benign solvents instead of toxic organic solvents, transforming what could be a limitation (water solubility issues) into an advantage (enhanced safety profile and reduced environmental impact) while maintaining product quality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid forms provide enhanced manufacturing properties and therapeutic efficacy, ensuring consistent quality and safety of PI3K inhibitor drug products.
Implementation Method 1
Development of solid forms of PI3K inhibitors, including crystalline forms, cocrystals, and amorphous forms
Data Source
AI summary
Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.